International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 566-572 www.ijprajournal.com ISSN: 2456-4494

A Review on Adverse Drug Reaction

[1]Yogita D. Pol , [2]Omkar A. Devade ,[3] Prathamesh Narale , [4]Sahil S.Gole , [5]Dipali Sirsam

[1,3,4,5]*Students, Professor, Yashoda Technical Campus Faculty of Pharmacy, Wadhe, Satara, India*

Date of Submission: 10-05-2025 Date of Acceptance: 20-05-2025

ABSTRACT:
Adverse Drug Reactions (ADRs) are unintended and harmful responses to medications that occur at normal therapeutic doses. They represent a significant challenge in clinical practice, contributing to increased morbidity, prolonged hospital stays, and additional healthcare costs. ADRs can range from mild allergic reactions to severe, life-threatening conditions, and they are a leading cause of patient safety concerns worldwide. Effective detection, monitoring, and reporting systems—such as pharmacovigilance—are essential for minimizing risks associated with drug therapy. This abstract highlights the classification, causes, and impact of ADRs, emphasizing the need for greater awareness among healthcare professionals and the public to improve medication safety and patientoutcomes.

Keywords: Adverse drug reaction, Pharmacovigilance, Medication Safety.

I. INTRODUCTION:

Adverse Drug Reactions, commonly known as ADRs, are unexpected or harmful effects caused by medicines when they are taken at normal prescribed doses. These reactions can range from minor symptoms like dizziness or rashes to serious conditions such as liver damage, kidney failure, or even death.

ADRs are a major concern in both hospital and outpatient settings, as they can lead to complications, longer hospital stays, and increased medical costs. Sometimes, they result in patients having to stop the medication or switch to a different treatment.

ADRs are typically grouped into two major categories:

Type A reactions are predictable and dose-related. These often result from the known pharmacological properties of the drug.

Type B reactions are unpredictable, not related to dose, and can occur due to individual sensitivities, allergies, or genetic factors.For example, a person taking a painkiller might experience nausea (a Type A reaction), while another might go into an allergic shock (a Type B reaction), despite taking the same dose.

Some ADRs are immediate, while others develop after prolonged use. In some cases, the reaction only becomes apparent when a drug interacts with another medication or food substance.Several factors increase the risk of ADRs. These include age (especially in children and the elderly), gender, liver or kidney disease, multiple medications, and a history of allergies. Older adults are more vulnerable because they often take many medications and may process drugs more slowly.

Monitoring for ADRs is an essential part of safe medication use. Healthcare professionals must regularly review patients' medications and educate them about possible side effects. Patients should also be encouraged to report any unusual symptoms or concerns after starting a new medication.

Pharmacovigilance—the science and activities related to detecting, assessing, and preventing ADRs—is a key part of public health. Many countries have systems in place to collect data on ADRs, helping to identify patterns and improve drug safety.

Organizations like the WHO, FDA (U.S.), and EMA (Europe) have dedicated departments to monitor drug safety. In India, the Pharmacovigilance Programme of India (PvPI) plays a similar role.

Reporting systems allow doctors, pharmacists, and even patients to submit information about suspected drug reactions. These reports help build a database that can be used to update medication guidelines, issue warnings, or even withdraw unsafe drugs from the market.

With the increasing use of medications in chronic disease management, cancer treatments, and personalized medicine, the potential for ADRs is also rising. This makes it more important than ever to improve awareness and prevention strategies.

Digital tools like electronic health records and AI-based alerts are also being used to identify

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 566-572 www.ijprajournal.com ISSN: 2456-4494

high-risk patients and reduce the chances of adverse reactions before they happen.

In summary, ADRs are a serious but often manageable aspect of modern healthcare. Through early detection, education, careful monitoring, and proper reporting, the risks can be reduced, making drug therapy safer and more effective for everyone.

Types Of ADR:

Type of ADR	Characteristic	Example
Type A (Augmented)	Predictable, dose-dependent, related to the drug's known effect	Bleeding with warfarin due to high dosage
Type B (Bizarre)	Unpredictable, not dose-related, often due to allergy or genetic factors	Anaphylaxis from penicillin
Type C (Chronic)	Occurs after long-term use of a drug	Adrenal suppression from prolonged corticosteroid use
Type D (Delayed)	Appears after a long time, even after stopping the drug	Cancer caused by chemotherapy drugs years later
Type E (End-of-use)	Happens when the drug is suddenly stopped (withdrawal reaction)	Seizures after stopping long-term benzodiazepine use
Type F (Failure)	Drug fails to work as expected, often due to interaction or resistance	Antibiotic resistance leading to treatment failure

Importance of ADR in clinical practice:

Adverse Drug Reactions (ADRs) are a critical concern in clinical practice because they directly affect patient safety, treatment outcomes, and the overall quality of healthcare. Recognizing and managing ADRs is a key responsibility for all healthcare professionals, including doctors, nurses, and pharmacists.

One of the most important reasons to monitor ADRs is to ensure patient safety. Some drug reactions can be severe, life-threatening, or even fatal if not identified early. Regular observation and reporting of side effects help in reducing harm and improving the effectiveness of treatment.

ADRs are also a common cause of hospital admissions, especially among the elderly and patients with chronic illnesses. They can lead to longer hospital stays, additional tests, and extra medications, which not only affect the patient's health but also increase the financial burden on the healthcare system.

In clinical practice, identifying ADRs helps in better decision-making. By knowing which drugs commonly cause problems and in which patients, healthcare providers can choose safer alternatives, adjust doses, or closely monitor for side effects.

Pharmacovigilance, the process of detecting and reporting ADRs, plays an essential role in improving drug safety. When clinicians report ADRs, it contributes to larger databases that regulatory agencies use to update drug guidelines, issue safety alerts, or even withdraw unsafe drugs from the market.

ADRs also highlight the need for individualized treatment. Not all patients react to drugs in the same way. Genetic differences, age, organ function, and other medications can all influence how someone responds to a drug. Monitoring for ADRs allows healthcare providers to tailor treatments to the individual needs of each patient.

From an ethical standpoint, healthcare providers have a duty to protect patients from

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 566-572 www.ijprajournal.com ISSN: 2456-4494

harm. Monitoring for ADRs, educating patients about possible side effects, and reporting unexpected reactions are all part of providing responsible and high-quality care.

In teaching hospitals and clinics, awareness of ADRs also helps in training future healthcare professionals to recognize, manage, and prevent drug-related problems.

In summary, understanding and managing ADRs is an essential part of clinical practice. It improves patient safety, supports rational prescribing, and strengthens the healthcare system's ability to provide effective, evidence-based care. By paying close attention to ADRs, clinicians can prevent harm, reduce costs, and improve health outcomes for patients.

Epidemiology of Adverse Drug Reactions (ADRs):

Adverse Drug Reactions (ADRs) are a significant public health issue worldwide. Epidemiology, in this context, involves studying the frequency, patterns, causes, and effects of ADRs in different populations. Understanding the epidemiology of ADRs helps in developing effective strategies to minimize risks and improve medication safety.

ADRs are responsible for a large number of hospital admissions. Studies from various countries have shown that around 5% to 10% of hospital admissions are due to drug-related adverse effects. In hospitalized patients, approximately 10% to 20% experience at least one ADR during their stay. These rates are often higher in older adults and people with multiple chronic diseases who are on several medications (polypharmacy).

The elderly population is especially vulnerable because of age-related changes in drug metabolism, reduced kidney and liver function, and the higher likelihood of taking multiple medications. Children are also at risk due to differences in body size, organ development, and dosing errors.

Gender, genetics, existing medical conditions, and lifestyle factors can influence the likelihood of experiencing ADRs. For instance, females are reported to have a higher risk of some types of drug reactions, possibly due to differences in body fat composition, hormonal levels, and enzyme activity.

Certain drug classes are more commonly associated with ADRs. These include antibiotics, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), antiepileptics, and chemotherapeutic agents. Many of these medications have narrow therapeutic ranges or interact with other drugs, increasing the risk of adverse effects.

Mechanism of Adverse Drug Reactions (ADRs):

Adverse Drug Reactions (ADRs) occur when a drug produces an unwanted or harmful effect under normal therapeutic conditions. Understanding the mechanisms behind ADRs is essential for predicting, preventing, and managing them effectively in clinical practice. These mechanisms can be broadly categorized into pharmacological, immunological, genetic, and idiosyncratic pathways.

1. **Pharmacological Mechanism (Type A Reactions):**

This type of ADR is directly related to the drug's known action — either due to exaggeration of the intended effect or effects on non-target tissues.

- Example: A patient taking a blood thinner like warfarin may experience bleeding if the drug concentration becomes too high.
- Mechanism: The drug acts on the intended receptor but with excessive intensity or duration.

2. Immunological Mechanism (Allergic Reactions / Type B Reactions)

These ADRs are triggered by the body's immune system reacting to a drug, even though the drug is not inherently harmful. They are not dose-dependent and may not be related to the drug's primary action.

- Example: Anaphylaxis after penicillin administration.
- Mechanism: The drug or its metabolite binds to body proteins, forming an antigen that triggers an immune response.

3. Idiosyncratic Reactions

These are rare, unpredictable reactions that do not fit into typical pharmacologic or allergic patterns. They often involve abnormal metabolism or unknown pathways.

- Example: Severe liver damage in a few individuals taking isoniazid.
- Mechanism: May involve abnormal metabolic processing or toxic metabolites in genetically susceptible individuals.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 566-572 www.ijprajournal.com ISSN: 2456-4494

4. Metabolic Mechanism

Some drugs are converted in the body to toxic metabolites, which can damage tissues or organs.

- Example: Acetaminophen overdose leading to liver damage.
- Mechanism: The drug is normally metabolized safely, but in large amounts, toxic byproducts accumulate and cause cellular injury.

Detection and Monitoring of Adverse Drug Reactions (ADRs):

The detection and monitoring of Adverse Drug Reactions (ADRs) are essential components of safe and effective healthcare. Identifying ADRs early can prevent serious harm, improve patient outcomes, and enhance the overall quality of treatment. Since ADRs can be unpredictable and sometimes delayed, a structured approach is needed to recognize, assess, and manage them efficiently.

1. Detection of ADRs

Detection involves recognizing a potential adverse effect that may be linked to a drug. This process can take place in hospitals, clinics, pharmacies, or even at home. Key methods include:

a. Clinical Observation

Healthcare providers observe patients for any unusual symptoms after starting a new drug. Sudden changes in physical condition, laboratory results, or patient complaints may point to an ADR.

b. Patient Reports

Patients themselves play a key role in detection. Educating patients to report side effects—especially new or worsening symptoms—helps in early identification of ADRs.

c. Electronic Health Records (EHR)

Modern systems can flag potential drug interactions or known high-risk drugs. Alerts generated by EHRs can assist clinicians in catching possible ADRs quickly.

d. Spontaneous Reporting Systems

Doctors, pharmacists, nurses, and even patients can report suspected ADRs to national pharmacovigilance centers. These reports help gather real-world safety data.

2. Monitoring of ADRs

Monitoring is an ongoing process to track the safety of medications over time. It includes collecting data, analyzing patterns, and taking action when needed. Methods include:

a. Pharmacovigilance Programs

- Many countries have national systems to monitor drug safety. For example:
- India has the Pharmacovigilance Programme of India (PvPI).
- The WHO operates a global database through Uppsala Monitoring Centre (UMC).
- The FDA's MedWatch program collects ADR data in the U.S.

b. Post-Marketing Surveillance

Once a drug is approved and used by the public, ongoing studies and monitoring are conducted to detect rare or long-term side effects not seen in clinical trials.

c. Targeted Drug Monitoring

Some drugs known to have serious side effects are closely monitored through routine blood tests or regular clinical evaluations. For example, patients on warfarin need frequent INR checks to avoid bleeding complications.

d. Prescription Audits

Reviewing prescriptions periodically can help identify irrational drug use, drug interactions, or high-risk combinations that may lead to ADRs.

e. Active Surveillance Systems

- These include structured follow-ups and surveys that proactively collect information from patients, especially after new medications are introduced.
- Importance of Detection and Monitoring
- Improves Patient Safety: Early detection can prevent worsening of reactions or avoid re-exposure to the harmful drug.
- Supports Rational Prescribing: Monitoring helps in updating treatment protocols and guidelines.
- Informs Regulatory Action: When ADRs are consistently reported, regulatory bodies can revise drug labels, issue warnings, or even withdraw unsafe medications.
- Promotes Research: Data collected through monitoring systems can be used to study risk factors and improve drug formulations.

Naranjo Algorithm for Causality Assessment:

The Naranjo Algorithm is a structured questionnaire used to determine how likely it is that a drug caused an adverse reaction. It helps

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 566-572 www.ijprajournal.com ISSN: 2456-4494

healthcare providers make objective decisions about whether a medication is responsible for a patient's symptoms.

How It Works:

The algorithm consists of 10 questions, each with a set of points. Based on the total score, the causality is categorized as Definite, Probable, Possible, or Doubtful.

Naranjo Questionnaire (Simplified):

Each question is answered with Yes, No, or Don't know.

Prevention Strategies for Adverse Drug Reactions (ADRs):

Adverse Drug Reactions (ADRs) can sometimes be serious or even life-threatening. Thankfully, many of them are preventable. Healthcare professionals and patients can take several steps to reduce the risk of ADRs.

1. Thorough Patient Assessment

- Get complete medical history including allergies, chronic illnesses, and previous drug reactions.
- Check liver and kidney function, as impaired organs can affect how drugs are processed.
- Review age, weight, and pregnancy status, which may influence drug dosing.

2. Rational Prescribing

- Use the lowest effective dose for the shortest time.
- Choose medications with fewer side effects when possible.
- Avoid polypharmacy (unnecessary use of multiple drugs), especially in the elderly.

3. Drug Interaction Checks

- Use tools or software to check for potential interactions between prescribed drugs.
- Be cautious with over-the-counter (OTC) medications and herbal supplements.

4. Patient Education

- Teach patients about:
- How and when to take their medicine
- Possible side effects to watch for
- When to seek medical help
- Emphasize not stopping medications suddenly without advice.

5. Monitoring and Follow-up

- Regularly monitor vital signs, lab tests, and drug levels (if needed).
- Schedule follow-ups to assess how the patient is responding to the medication.
- Detect side effects early to prevent complications.

6. Pharmacogenetic Testing (if available)

- Helps identify genetic differences that affect drug metabolism.
- Personalized drug selection can reduce ADR risk.

7. Report ADRs

- Encourage reporting of any suspected ADRs to national pharmacovigilance centers.
- This improves drug safety data and helps prevent future cases.

8. Team-Based Approach

- Involve pharmacists, nurses, and doctors in medication management.
- Pharmacists can help with dose adjustments, interaction checks, and education.

By combining these strategies, the chances of ADRs can be greatly minimized, leading to safer and more effective treatment for patients.

Recent Advances in ADR Detection and Management:

1. Pharmacogenomics (Gene-Based Therapy)

- **What it is:** Using genetic testing to understand how an individual's genes affect their response to drugs.
- **Why it matters:** Certain gene variations can make people more likely to experience severe ADRs.
- **Example:** Testing for HLA-B*1502 before prescribing carbamazepine to prevent Stevens-Johnson Syndrome in Asian populations.

2. Artificial Intelligence (AI) and Machine Learning

- **Use:** AI models are now being used to predict the likelihood of ADRs by analyzing large datasets from electronic health records and patient reports.
- **Benefit**: Helps doctors identify at-risk patients earlier and customize treatment.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 566-572 www.ijprajournal.com ISSN: 2456-4494

- **Example:** AI tools that scan clinical notes to detect patterns indicating an ADR before it's clinically obvious.

3. Mobile Apps and Digital Reporting Tools

- **New trend:** Patients and healthcare workers can now report suspected ADRs using mobile apps developed by national pharmacovigilance centers.
- **Why it's useful:** Encourages real-time and easier ADR reporting, increasing data quality and speed of response.
- **Example:** The MedWatcher app and WHO's VigiMobile**.**

4. Big Data and Global Pharmacovigilance Networks

- **What's new:** Integration of data across countries and health systems to detect rare or serious ADRs faster.
- **Tools:** WHO's VigiBase, FDA's FAERS (Adverse Event Reporting System).
- **Advantage:** Early signal detection at a global scale, especially for new drugs or vaccines.

5. Real-World Evidence (RWE)

- **Definition:** Using real patient data (from hospitals, insurance claims, etc.) to understand how drugs perform outside of clinical trials.
- **Impact:** Helps identify ADRs that may not have appeared during initial studies.
- **Example:** Post-marketing studies for COVID-19 vaccines to detect rare side effects.

Challenges and Limitations of Adverse Drug Reactions (ADRs):

Despite progress in pharmacovigilance, ADRs still remain a significant concern in healthcare. There are several barriers and limitations that make their detection, prevention, and management difficult.

1. Underreporting of ADRs

- **Problem**: Many ADRs go unreported by healthcare professionals and patients.
- **Why:** Lack of awareness, time constraints, or thinking the reaction is too minor to report.
- **Impact:** Slows down the detection of harmful or rare drug reactions.

2. Difficulty in Establishing Causality

- **Problem**: It's often hard to confirm whether a drug truly caused a reaction.
- **Why**: Patients may be on multiple medications, or have underlying conditions that mimic ADRs.
- **Example:** A rash may be due to a drug, but could also be an allergy or infection.

3. Polypharmacy

- **Problem:** Taking multiple drugs increases the risk of interactions and side effects.
- **Common in:** Older adults or those with chronic illnesses.
- **Challenge:** Harder to pinpoint which drug caused the reaction.

4. Individual Variation

- **Problem:** People's responses to drugs vary due to age, gender, genetics, and organ function.
- **Result:** What's safe for one person may cause severe side effects in another.

5. Limitations of Clinical Trials

- **Issue:** Clinical trials often involve limited sample sizes and specific patient groups.
- **Consequence:** Rare or long-term ADRs may only appear after the drug is approved and widely used.

6. Delayed Reactions

- **Problem:** Some ADRs occur days, weeks, or even months after starting a drug.
- **Effect:** Makes it harder to connect the reaction to the drug.

7. Lack of Standardized Reporting Systems

- **Global challenge:** Different countries use different methods and platforms for ADR reporting.
- **Result:** Inconsistent data collection and difficulty sharing information internationally.

II. CONCLUSION:

Adverse Drug Reactions (ADRs) remain a significant concern in healthcare, affecting patient safety, treatment outcomes, and healthcare costs. While many ADRs are preventable, challenges such as underreporting, polypharmacy, and individual variations in drug response continue to make their management complex. Efforts to reduce ADRs rely on early detection, patient education, careful prescribing practices, and stronger pharmacovigilance systems. A multidisciplinary approach involving healthcare providers, patients, regulatory authorities, and researchers is essential for minimizing the risks.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 566-572 www.ijprajournal.com ISSN: 2456-4494

Future Directions:

The future of ADR management is moving toward personalized, data-driven, and technology-supported approaches. Here are some promising directions:

1. Precision Medicine

- Using genetic testing and biomarkers to predict individual risk for specific drug reactions.
- Tailoring drug choices and dosages based on the patient's genetic profile.

2. Artificial Intelligence and Big Data

- Leveraging AI to analyze electronic health records and detect ADR patterns earlier.
- Predictive models can help identify high-risk patients before ADRs occur.

3. Digital Reporting Platforms

- Expanding mobile apps and online tools to make ADR reporting easier for both patients and healthcare professionals.
- Encouraging real-time, user-friendly reporting can improve data collection.

4. Global Collaboration

- Strengthening international networks like WHO's Uppsala Monitoring Centre to detect and respond to global drug safety signals.
- Promoting standardized ADR reporting systems across countries.

5. Enhanced Education and Training

- Increasing awareness among healthcare workers and patients about how to recognize and report ADRs.
- Incorporating ADR training into medical and pharmacy education.

6. Post-Marketing Surveillance Innovations

- Continuous safety monitoring of drugs after approval through real-world evidence (RWE) and active surveillance systems.
- Ensures long-term and rare ADRs are caught early.

REFERENCES:

[1]. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-259.

[2]. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinican's guide to terminology, documentation, andreporting. An Intern. Med 2004; 140: 795-801.

[3]. Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, ed. Textbook of adverse drug reaction. Newyork: oxford university press 1977:10.

[4]. 4.. Dr. Ramesh KG, Dr. Parloop AB, Dr. Mahesh DB. Elements of clinical pharmacy, 4th edn:2008-2009, B.S. Shah prakashan; page no-109-114.

[5]. Pirmohamed M, Park BK. Adverse drug reactions: back to the future. British j Pharmacol 2003; 55: 486-492.

[6]. Park B, Pirmohamed M, Kitteringham N. idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin pharmacol 1992; 34: 377-395.

[7]. Bennett PN, Brown MJ. Clinical Pharmacology. Tenth edition. Churchill Livingstone, Edinburgh, 2008.

[8]. Tarantino G. Drug-induced liver injury: is it somehow foreseeable? World J Gastroenterol 2009; 15: 2817-2833.

[9]. Elbe D, Savage R. How does this happen?. Part 1: mechanisms of adverse drug reactions associated with psychotropic medications. J Can Aca Child Adol Psychiat 2010; 19: 40-45.

[10]. Hadi MA, Neoh CF, Zin RM, Elrggal ME, Cheema E. Pharmacovigilance: pharmacists' perspective on spontaneous adverse drug reaction reporting. Integrated Pharmacy Res Pract. 2017;6:91–8.

[11]. Nivya K, Sri Sai Kiran V, Ragoo N, Jayaprakash B, Sonal Sekhar M. Systemic review on drug related hospital admissions - a pubmed based search. Saudi Pharmaceut J. 2015;23(1):1–

[12]. Jokanovic N, Wang KN, Dooley MJ, Lalic S, Tan EC, Kirkpatrick CM, Bell JS. Prioritizing interventions to manage polypharmacy in Australian aged care facilities. Res Soc Adm Pharm. 2017;13(3):564–74